Sygnature Chemical Services Strengthens Scientific Team: Dr Michael Knaggs Appointed As Head Of Computational Chemistry
1/21/2010 1:24:29 PM
Nottingham, UK 21st January 2010 – Sygnature Chemical Services Ltd., a leading UK-based provider of premium discovery chemistry services to the global pharmaceutical industry, today announced the appointment of Dr Michael (“Mick”) Knaggs as Head of Computational Chemistry.
Dr Simon Hirst, Sygnature’s Chief Executive Officer commented, “I welcome Mick to Sygnature Chemical Services, he is a great addition to our scientific team and has joined Sygnature at an opportune time. Mick has over 10 years computational chemistry experience in the pharmaceutical industry and academia in the UK and USA. He has good experience of undertaking virtual screening projects (structure-based and ligand-based approaches) in a variety of targets (CNS, tropical diseases, anti-virals anti-bacterials etc), pharmacophore modelling, QSAR and library design; as well as protein modelling and simulation work. Sygnature has experienced a growing interest in its computational chemistry services over the past few months, both as a stand-alone service and to support medicinal chemistry-based projects. Mick is already contributing his expertise into several on-going projects and has been involved in a number of proposals for new projects which will involve computational chemistry in some form.
Dr Michael Knaggs added, “I am pleased to join the company at a time when Sygnature has been experiencing an increase in interest in its discovery chemistry services, and has just formed a strategic alliance with Cyprotex to provide a fully-integrated discovery chemistry/DMPK services. Computational chemistry forms a key component of the drug discovery process – from hit identification through virtual screening to guiding structural modifications to enhance potency and selectivity during medicinal chemistry-driven optimisation. I am looking forward to working with Simon and the rest of the Sygnature team.”
About Sygnature Chemical Services Ltd.
Sygnature Chemical Services, founded in 2004, is a leading Nottingham, UK-based provider of premium discovery chemistry services (medicinal chemistry, synthetic chemistry, array/focused library and computational chemistry). The company delivers high value and quality to its clients by applying in-house scientific expertise and ‘state-of-the-art’ technologies to the discovery of novel drug candidates. Sygnature’s team of 34 industry-experienced chemists (75% with PhDs) undertakes key elements of the drug discovery process, such as hit identification, hit-to-lead and lead optimisation, to afford novel compounds in a time-efficient and cost-effective manner. We work closely with our clients’ scientists to accelerate their drug candidates into development and thereby increase the value of their R&D discovery programmes. Over the past five years, Sygnature has established an enviable reputation and excellent track record of success with an international client base. For more information on Sygnature visit www.sygnaturechem.com.